China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...

A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion. Novo Nordisk's crown jewel is ...

(Reuters) - Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday ...

Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...

Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.

The diabetes medicine Ozempic has been a veritable cash cow for Novo Nordisk (NYSE: NVO). The company's revenue, earnings, and stock price have been on a tear in recent years -- and no single drug ...